Innovative strength lies in the conceptual change our results will effect: in the way inherited and age-related disease is viewed and approached diagnostically and therapeutically. Inherited diseases are now tackled with symptom treatment, lifestyle and possibly gene therapy. Age-related protein-aggregation diseases are approached mostly with lifestyle changes, some non-curative medication, or rather invasive technology such as deep-brain stimulation in Parkinson’s disease.
Our approach aims to open the gates to fast and therapy-directed analysis of patient-specific protein defects. Therapy in our proposal will be a pill. With a fair chance that this pill will come close to curing the disease.